Kristen Kluska

Stock Analyst at Cantor Fitzgerald

(4.29)
# 432
Out of 4,981 analysts
239
Total ratings
42.53%
Success rate
21.03%
Average return

Stocks Rated by Kristen Kluska

Ultragenyx Pharmaceutical
Sep 5, 2025
Reiterates: Overweight
Price Target: $105
Current: $29.54
Upside: +255.45%
PTC Therapeutics
Sep 3, 2025
Reiterates: Overweight
Price Target: $118
Current: $59.73
Upside: +97.56%
Monopar Therapeutics
Aug 27, 2025
Reiterates: Overweight
Price Target: $74
Current: $53.59
Upside: +38.09%
Supernus Pharmaceuticals
Aug 6, 2025
Maintains: Overweight
Price Target: $42$46
Current: $44.45
Upside: +3.49%
Rigel Pharmaceuticals
Aug 6, 2025
Maintains: Neutral
Price Target: $23$32
Current: $37.60
Upside: -14.89%
Eupraxia Pharmaceuticals
Jul 24, 2025
Initiates: Overweight
Price Target: $11
Current: $5.27
Upside: +108.73%
Zevra Therapeutics
Jul 10, 2025
Maintains: Overweight
Price Target: $25$29
Current: $7.39
Upside: +292.42%
Solid Biosciences
May 22, 2025
Assumes: Overweight
Price Target: $16
Current: $5.67
Upside: +182.19%
Fulcrum Therapeutics
May 15, 2025
Upgrades: Overweight
Price Target: $10
Current: $7.09
Upside: +41.04%
Capricor Therapeutics
May 14, 2025
Reiterates: Overweight
Price Target: $30
Current: $6.25
Upside: +380.00%
Maintains: Overweight
Price Target: $163$81
Current: $17.52
Upside: +362.33%
Reiterates: Overweight
Price Target: $7
Current: $3.01
Upside: +132.95%
Maintains: Overweight
Price Target: $67$123
Current: $51.99
Upside: +136.58%
Reiterates: Overweight
Price Target: $90
Current: $3.06
Upside: +2,841.18%
Reiterates: Overweight
Price Target: $7
Current: $1.78
Upside: +294.37%
Maintains: Overweight
Price Target: $99$132
Current: $58.93
Upside: +123.99%
Reiterates: Overweight
Price Target: $25
Current: $15.52
Upside: +61.08%
Reiterates: Overweight
Price Target: $67
Current: $24.66
Upside: +171.70%
Reiterates: Overweight
Price Target: $21
Current: $7.75
Upside: +171.14%
Reiterates: Overweight
Price Target: $29
Current: $7.94
Upside: +265.24%
Initiates: Overweight
Price Target: $17
Current: $5.16
Upside: +229.78%
Initiates: Overweight
Price Target: $8
Current: $2.83
Upside: +182.69%
Maintains: Overweight
Price Target: $28$58
Current: $14.90
Upside: +289.26%
Reiterates: Overweight
Price Target: $11
Current: $2.43
Upside: +353.61%
Reiterates: Overweight
Price Target: $18
Current: $5.86
Upside: +207.43%
Reiterates: Overweight
Price Target: $14
Current: $4.10
Upside: +241.46%
Reiterates: Overweight
Price Target: $13
Current: $1.50
Upside: +769.57%
Reiterates: Overweight
Price Target: $21
Current: $1.63
Upside: +1,192.31%
Reiterates: Overweight
Price Target: $6
Current: $1.31
Upside: +358.02%
Downgrades: Neutral
Price Target: $90$20
Current: $1.05
Upside: +1,813.88%
Reiterates: Overweight
Price Target: $23
Current: $3.81
Upside: +503.67%
Reiterates: Overweight
Price Target: $900
Current: $1.54
Upside: +58,341.56%
Initiates: Overweight
Price Target: $400
Current: $2.81
Upside: +14,160.25%
Downgrades: Neutral
Price Target: $1,250$85
Current: $0.90
Upside: +9,292.78%
Initiates: Overweight
Price Target: $180
Current: $6.96
Upside: +2,488.07%
Initiates: Overweight
Price Target: $180
Current: $2.80
Upside: +6,320.55%
Downgrades: Neutral
Price Target: $15$11
Current: $1.16
Upside: +852.38%
Initiates: Overweight
Price Target: $60
Current: $0.94
Upside: +6,255.93%
Initiates: Overweight
Price Target: $90
Current: $1.24
Upside: +7,158.06%
Assumes: Overweight
Price Target: $10,620$2,520
Current: $1.48
Upside: +170,170.27%
Initiates: Overweight
Price Target: $160
Current: $0.48
Upside: +33,261.13%